ClinicalTrials.gg
CompletedNCT01498822OPTIMALUpdated Aug 20, 2015Results posted

Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy

A Phase 4 interventional study of Levetiracetam and Oxcarbazepine in Epilepsy, sponsored by Korea UCB Co., Ltd.. Completed at 23 sites in Korea, Republic of. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-08-20.

Primary conditionEpilepsies, PartialRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Epilepsies, Partial
Why
  1. The study's title name Epilepsies, Partial, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Korea UCB Co., Ltd. (part of UCB S.A.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.

Enrollment
3rd of 18
353 · median 173
Started
2011
with 2 others
Phase 4
7 of 18
none open now
Registered
15th of 18
by date
Lead sponsor
1 of 18
Korea UCB Co., Ltd.

Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is one of 7 in phase 4, and was the 15th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing levetiracetam in Epilepsies, Partial as a file.
02

Study summary

To evaluate the long term effectiveness of Levetiracetam (LEV) monotherapy on Treatment Failure Rate in subjects with newly diagnosed partial onset seizures with or without secondary generalized seizures, compared to Oxcarbazepine (OXC) monotherapy over 50 weeks from the first dose

Read the detailed description

The study duration consists of the following periods:

  • Baseline period of one week: Week -1
  • Titration period of two weeks: Week 0 to Week 1
  • Treatment period of 48 weeks: Week 2 to Week 50
03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Levetiracetam
  • Oxcarbazepine
  • treatment failure
  • partial epilepsy
04

In context

Epilepsies, Partial Reclassified

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

This study's enrollment of 353 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.

Browse Epilepsies, Partial studies →

Lead sponsor

This is the only study on the registry with Korea UCB Co., Ltd. as lead sponsor.

Compared within Epilepsies, Partial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects from 16 to 80 years, inclusive. Vulnerable subjects (e.g., under 20 years or subject with learning disability but judged to be capable to understand) may only be included where legally permitted and ethically accepted
  • Subjects with newly or recently diagnosed epilepsy having experienced unprovoked partial seizures (IA, IB, IC with clear focal origin), that are classifiable according to the International Classification of Epileptic seizure (1981). Undiscriminated subjects between IC and IIE could be included
  • Subjects with at least 2 unprovoked seizures separated by a minimum of 48 hours in the year preceding randomization out of which at least 1 unprovoked seizure in the 6 months preceding randomization
  • Subjects with documented evidence of EEG and brain MRI or CT scan in medical records which were performed within 1 year prior to Visit 1 (V1)
  • Subjects have no treatment with anti-epileptic drugs in the 6 months preceding this study. The treatment for acute seizure control is acceptable with a maximum of 2 weeks duration and if the treatment was stopped at least 1 week before V1. For Phenobarbital and Phenobarbital derivatives, a minimum of 4 weeks wash-out is requested before V1

Exclusion criteria

Exclusion Criteria:

  • Subject has a current or previous diagnosis of pseudoseizures, conversion disorders, or other non-epileptic ictal events which could be confused with seizures
  • Subject taking 1 or more of the following medications on a regular basis within 28 days prior to Visit 1: neuroleptics, monoamine oxidase (MAO) inhibitors and narcotic analgesics
  • Subject taking any within 28 days prior to Visit 1
  • Subject has a history of suicide attempt, has received professional counseling for suicidal ideation, or is currently experiencing active suicidal ideation
  • Subject has a seizure disorder characterized primarily by isolated auras (ie, simple partial seizures without observable motor signs)
  • Subject suffering from seizures other than partial (IA, IB, IC, with clear focal origin) seizures
  • Subject has a history of status epilepticus within last 3-month period prior to Visit 1
  • Subject has seizures that are uncountable due to clustering (ie, an episode lasting less than 30 minutes in which several seizures occur with such frequency that the initiation and completion of each individual seizure cannot be distinguished) during the 12-week period prior to Visit 1 and/or during the Screening Period
  • Body weight is lower than 40 kg (\< 40 kg)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Levetiracetam twice a day treatment group

    Drug: Levetiracetam

  • Active comparator
    Oxcarbazepine

    Oxcarbazepine twice a day treatment group

    Drug: Oxcarbazepine

Interventions

  • 250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks

  • 150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)

07

What researchers measure

Primary outcomes

  1. Percentage of Subjects With a Treatment Failure

    Treatment failure is defined as (1) Dropout due to related intolerable adverse event, lack of efficacy or need for addition of another Antiepileptic Drug (AED), or (2) need of a 1-step down-Titration, within 50 weeks from the first dose of study medication.

    Time frame: Week 0 (First Dose) to Week 50

Secondary outcomes

  1. Time to the First Seizure Defined as the Time From the First Dose of Medication to the Occurrence of the First Seizure During the 48 Weeks Treatment Period

    Time frame: From Week 2 to Week 50 (During Treatment Period )

  2. Percentage of Subjects Who Achieved Seizure Freedom for 24 Consecutive Weeks During the 48 Weeks Treatment Period at Any Time

    24-week Seizure Freedom (rate) defined as the number and percentage of subjects who achieved seizure freedom for 24 consecutive weeks during the Treatment Period at any time

    Time frame: From Week 2 to Week 50 (During Treatment Period )

  3. Percentage of Subjects Who Achieved Seizure Freedom During the 48 Weeks Treatment Period

    48-week Seizure Freedom (rate) defined as the number and percentage of subjects who achieved seizure freedom during the Treatment Period

    Time frame: From Week 2 to Week 50 (During Treatment Period )

08

Results

Posted Aug 20, 2015

Participant flow

This study started to enroll subjects in June 2011. A total of 27 investigators enrolled 353 subjects at 23 sites in Korea.

Participant flow — Overall Study
MilestoneLevetiracetamOxcarbazepine
Started175178
Completed121122
Not completed5456
Withdrew: Protocol violation84
Withdrew: Other reason52
Withdrew: Lack of efficacy72
Withdrew: Ae, non-serious non-fatal817
Withdrew: Sae, non-fatal22
Withdrew: Adverse event, serious fatal11
Withdrew: Withdrawal by subject1525
Withdrew: Lost to follow-up83

Outcome measures

PrimaryPercentage of Subjects With a Treatment Failure

Treatment failure is defined as (1) Dropout due to related intolerable adverse event, lack of efficacy or need for addition of another Antiepileptic Drug (AED), or (2) need of a 1-step down-Titration, within 50 weeks from the first dose of study medication.

Time frame:
Week 0 (First Dose) to Week 50
Reported as:
Number · percentage of subjects
Percentage of Subjects With a Treatment Failure
percentage of subjectsPer Protocol Set (LEV Treated Subjects)Per Protocol Set (OXC Treated Subjects)
Percentage of Subjects With a Treatment Failure12.723.4
Statistical analysis
  • Per Protocol Set (LEV Treated Subjects) vs Per Protocol Set (OXC Treated Subjects) · Wald methodology · Absolut difference: -10.7 · 95% CI -20.2 to -1.2Absolute difference in treatment failure rates of LEV versus OXC is defined as "Treatment Failure Rate LEV" minus "Treatment Failure Rate OXC".
SecondaryTime to the First Seizure Defined as the Time From the First Dose of Medication to the Occurrence of the First Seizure During the 48 Weeks Treatment Period
Time frame:
From Week 2 to Week 50 (During Treatment Period )
Reported as:
Median · months
Time to the First Seizure Defined as the Time From the First Dose of Medication to the Occurrence of the First Seizure During the 48 Weeks Treatment Period
monthsFull Analysis Set (LEV Treated Subjects)Full Analysis Set (OXC Treated Subjects)
Time to the First Seizure Defined as the Time From the First Dose of Medication to the Occurrence of the First Seizure During the 48 Weeks Treatment Period7.556 (NA to NA)NA (NA to NA)
SecondaryPercentage of Subjects Who Achieved Seizure Freedom for 24 Consecutive Weeks During the 48 Weeks Treatment Period at Any Time

24-week Seizure Freedom (rate) defined as the number and percentage of subjects who achieved seizure freedom for 24 consecutive weeks during the Treatment Period at any time

Time frame:
From Week 2 to Week 50 (During Treatment Period )
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Achieved Seizure Freedom for 24 Consecutive Weeks During the 48 Weeks Treatment Period at Any Time
percentage of subjectsFull Analysis Set (LEV Treated Subjects)Full Analysis Set (OXC Treated Subjects)
Percentage of Subjects Who Achieved Seizure Freedom for 24 Consecutive Weeks During the 48 Weeks Treatment Period at Any Time53.858.5
SecondaryPercentage of Subjects Who Achieved Seizure Freedom During the 48 Weeks Treatment Period

48-week Seizure Freedom (rate) defined as the number and percentage of subjects who achieved seizure freedom during the Treatment Period

Time frame:
From Week 2 to Week 50 (During Treatment Period )
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Achieved Seizure Freedom During the 48 Weeks Treatment Period
percentage of subjectsFull Analysis Set (LEV Treated Subjects)Full Analysis Set (OXC Treated Subjects)
Percentage of Subjects Who Achieved Seizure Freedom During the 48 Weeks Treatment Period34.740.9

Adverse events

Collected over Adverse Events were collected up to 57 Weeks from Visit 1 (Week -1) to the end of the post-treatment period (down-titration visit, safety follow-up visit).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam—15/173 (8.7%)67/173 (38.7%)
Oxcarbazepine—15/174 (8.6%)93/174 (53.4%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventLevetiracetamOxcarbazepine
ConvulsionNervous system disorders4/1735/174
Cardiac arrestCardiac disorders0/1732/174
Abdominal painGastrointestinal disorders1/1730/174
DiarrhoeaGastrointestinal disorders1/1730/174
Chest discomfortGeneral disorders1/1730/174
Fibula fractureInjury, poisoning and procedural complications1/1730/174
Thermal burnInjury, poisoning and procedural complications1/1730/174
Tibia fractureInjury, poisoning and procedural complications1/1730/174
Back painMusculoskeletal and connective tissue disorders1/1731/174
Flank painMusculoskeletal and connective tissue disorders1/1730/174
Most frequent other events
Most frequent other events
EventLevetiracetamOxcarbazepine
DizzinessNervous system disorders25/17350/174
HeadacheNervous system disorders25/17336/174
SomnolenceNervous system disorders22/17324/174
NasopharyngitisInfections and infestations14/17319/174
RashSkin and subcutaneous tissue disorders3/17313/174

Baseline characteristics

Baseline Characteristics refer to the Randomized Set, consisting of all subjects who were randomized in this study.

Age, Categorical
Age, Categorical(Participants)LevetiracetamOxcarbazepineTotal Title
<=18 years141327
Between 18 and 65 years145143288
>=65 years162238
Age, Continuous
Age, Continuous(years)LevetiracetamOxcarbazepineTotal Title
Mean39.5 ± 16.742.7 ± 17.341.1 ± 17.0
Sex: Female, Male
Sex: Female, Male(Participants)LevetiracetamOxcarbazepineTotal Title
Female8479163
Male9199190
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LevetiracetamOxcarbazepineTotal Title
American Indian or Alaska Native000
Asian174178352
Native Hawaiian or Other Pacific Islander000
Black or African American000
White101
More than one race000
Unknown or Not Reported000
09

Study locations

23 sites
  • 05
    Busan, Korea, Republic of
  • 10
    Busan, Korea, Republic of
  • 16
    Busan, Korea, Republic of
  • 06
    Daejeon, Korea, Republic of
  • 18
    Daejeon, Korea, Republic of
  • 23
    Gangwon-Do, Korea, Republic of
  • 08
    Goyang-si, Korea, Republic of
  • 09
    Goyang-si, Korea, Republic of
  • 07
    Gwangju, Korea, Republic of
  • 22
    Jung-Gu, Korea, Republic of
  • 14
    Seongnam-si, Korea, Republic of
  • 01
    Seoul, Korea, Republic of
  • 02
    Seoul, Korea, Republic of
  • 03
    Seoul, Korea, Republic of
  • 04
    Seoul, Korea, Republic of
  • 11
    Seoul, Korea, Republic of
  • 12
    Seoul, Korea, Republic of
  • 13
    Seoul, Korea, Republic of
  • 15
    Seoul, Korea, Republic of
  • 17
    Seoul, Korea, Republic of
  • 20
    Seoul, Korea, Republic of
  • 21
    Seoul, Korea, Republic of
  • 19
    Ulsan, Korea, Republic of
10

References and documents

Publications

  • Kim JH, Lee SK, Loesch C, Namgoong K, Lee HW, Hong SB; Korean N01367 Study Group. Comparison of levetiracetam and oxcarbazepine monotherapy among Korean patients with newly diagnosed focal epilepsy: A long-term, randomized, open-label trial. Epilepsia. 2017 Apr;58(4):e70-e74. doi: 10.1111/epi.13707. PubMed 28395124 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2011
First posted
Dec 23, 2011
Start
Jun 2011
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Aug 20, 2015
Last update
Aug 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01498822
Responsible party
Sponsor
First posted
Dec 23, 2011
Start date
Jun 2011
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Aug 20, 2015
Last update
Aug 20, 2015

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion